Strategic Pharmacy Business Initiative  

RxLink - Spirit of the Independent Pharmacist!

Pharmacy News

Drug Updates

HMO News

Events for Pharmacists

Clinical Pharmacy

Compounding Pharmacy

HomeCare Pharmacy

Long-Term Care 

RxLink Nutrition


Pharmacy Staffing

Pharmacy Affiliates

Independent Voices

E-mail us

Feedback to RxLink

Consulting Services

Contact RxLink

RxLink Archives









From Victory Pharma

October 11, 2004

Dear RxLink Pharmacist:

Effective immediately, Victory Pharma, Inc. is pleased to announce the new single source branded formulations of the Duratess product line. This includes Duratess Tablets, Duratess GP Tablets, Duratess DM Elixir, and Duratess HD Elixir. Indications and dosing will remain identical to the previous formulations. There is no generic equivalent to any of these products as these formulations are protected under patents that are pending with the U.S. Patent and Trademark Office.

The following products no longer contain pseudoephedrine: Duratess Tablets, Duratess GP Tablets and Duratess HC Elixir. Instead, the new formulations will contain phenylephrine as a decongestant. The move away form pseudoephedrine was spurred by market events (e.g. legislation passed by several states which addresses theft, diversion, and special handling requirements). Victory Pharma, Inc. is sensitive to concerns associated with these actions and is taking a proactive stance by replacing pseudoephedrine in its product line.

The new formulations will be available for you to order through your primary and secondary wholesalers the week of October 11. Please update your system appropriately with the new NDC numbers.

PRODUCT                                     OLD NDC                        NEW NDC

Duratess Tablets                            68453-612-10                 68453-615-10

Duratess GP Tablets                       68453-640-10                 68453-645-10

Duratess DM Elixir                          50474-630-16                 68453-500-16

Duratess HD Elixir                           59474-610-16                 68453-400-16

Should you have any questions regarding these products, please contact out customer service department at 866-427-6819.

Thank you for your assistance.

Best regards,

Victory Pharma, Inc.

Duratess is contraindicated in individuals with known hypersensitivity to sympathomimetics, severe hypertension, or patients receiving MAO inhibitors.


To: RxLink®

From: NDC Health

October 5, 2004

You asked-We listened-We delivered

NDCHealth is pleased to announce our new Pre % Post editing-Action View report, available only through the Internet. Among many benefits, the Action View report:

-Allows you to focus on the prescriptions where you can make the most impact.

-Lists prescriptions where opportunities exist to make corrections to claim and resubmit.

-Helps increase your overall reimbursement.

When you register for web-based reporting, you will automatically receive the Action View report. To register for web-based reporting- and to receive the Action View report-go to the Internet address below and use your NABP number and your Authorization Code.


Upon registering successfully, we will immediately provide you a login and a system-generated password. Your first web-based report will be available next month. It's that easy.

For further assistance, call the NDCHealth Pharmacy Support Center at 800-388-2316


Donna Moore

Manager, Pharmacy Services-Independent Operations

Back to Previous Page
©2004 RxLink The Pharmaceutical Care Network!


RxLink.Biz RxLink: RxLink LLC - Opportunities for Pharmacists: Pharmacy Franchise Ownership - Pharmacy Jobs Oppotunities - Pharmacy Business Development and Improvement RxLink LLC - Pharmacy Business Consulting Services © 2007 All Rights Reserved